InflaRx N.V. filings document foreign-private-issuer reporting for a Nasdaq-listed biopharmaceutical company focused on complement-targeted anti-inflammatory therapeutics. Form 6-K reports furnish interim financial statements, management discussion and analysis, press releases on izicopan and vilobelimab programs, Nasdaq compliance notices, annual general meeting materials and shareholder voting results.
The company’s regulatory records also describe capital-structure matters, including ordinary-share offerings under an effective Form F-3 shelf registration statement and incorporation by reference into Form S-8 registration statements. Governance disclosures cover Dutch statutory annual accounts, audit instructions, director reappointments, board authorization matters and related shareholder approvals.